Medivation

J&J: We're Creaming Medivation, Boehringer, Bristol And Pfizer
Forbes
Thu, 05/23/13 - 10:44 am
JNJ
Medivation
Boehringer Ingelheim
Pfizer
Bristol-Myers Squibb
Xarelto
Zytiga
Medivation Inc.: Today's Featured Drugs Laggard
The Street
Sat, 05/11/13 - 11:07 am
Medivation
Medivation Earnings: Your Sneak Peek to the Big Announcement
Wall St. Cheat Sheet
Thu, 05/9/13 - 08:40 am
devices
Medivation
earnings
Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential
Seeking Alpha
Sat, 05/4/13 - 10:32 am
Vertex Pharmaceuticals
Pharmacyclics
Novartis
Celsion
Peregrine Pharmaceuticals
Prana
Navidea Biopharmaceuticals
Cardinal Health
ONYX Pharmaceuticals
Bayer
Sarepta
Hyperion Therapeutics
Amarin
Medivation
Astellas
JNJ
Trius
Sangamo BioSciences
This Week in Biotech
Motley Fool
Sun, 04/28/13 - 12:13 pm
Avanir
Medivation
Pfizer
Achillion
Theravance
Gilead Sciences
GSK
Aragon Pharma's ARN-509 Is No Near-Term Threat to Medivation
Yahoo/Minyanville
Tue, 04/23/13 - 03:30 pm
Medivation
Aragon
ARN-509
prostate cancer
Can Bristol-Myers Squibb Compete In Immuno-Oncology?
Seeking Alpha
Mon, 04/8/13 - 11:03 am
immuno-oncology
cancer
Bristol-Myers Squibb
AbbVie
Ariad Pharmaceuticals
JNJ
Eli Lilly
Novartis
Pfizer
Medivation
Erbitux
Yervoy
Sprycel
Orencia
Medivation, Astellas Pharma provide update on Phase 3 PREVAIL
Yahoo/Fly on the Wall
Mon, 04/1/13 - 10:49 am
Astellas
Medivation
metastatic castration-resistant prostate cancer
prostate cancer
Xtandi
Tackling Cancer: Prostate Cancer's Biggest Current and Upcoming Players
Motley Fool
Wed, 03/6/13 - 09:49 am
prostate cancer
Zytiga
JNJ
Xtandi
Medivation
Astellas
Provenge
Dendreon
Jevtana
Sanofi
Medivation Earnings Call Nuggets: Gross to Net Conversion and the Pre-Chemo Market
Wall Street Cheat Street
Sun, 03/3/13 - 11:20 am
Medivation
earnings
1 Overblown Biotech Selloff
Motley Fool
Sat, 03/2/13 - 03:57 pm
Medivation
Medivation falls after analyst says Xtandi must overcome obstacles
The Fly on the Wall
Thu, 02/28/13 - 11:27 am
Medivation
Xtandi
prostate cancer
5 Can't-Miss Health-Care Events This Week
Motley Fool
Sun, 02/24/13 - 02:29 pm
Onyx
Bayer
Zogenix
Ariad
Questcor
Medivation
Johnson & Johnson's Pioneering Zytiga And Its Competitors
Seeking Alpha
Sun, 02/24/13 - 02:26 pm
Zytiga. ARN-509
Xtandi
prostate cancer
Medivation
JNJ
Astellas
Aragon
Tokai
13 Biotech Stock Predictions for 2013
TheStreet.com
Wed, 01/2/13 - 12:18 pm
Eisai
Sarepta
Arena Pharmaceuticals
Amarin
Gilead
Biomarin
Onyx
Medivation
Achillion
Incyte
Cell Therapeutics
Celgene
NPS Pharmaceuticals
Aegerion
Roche
Biogen Idec
Ariad Pharmaceuticals
Alexza
Navidea
Aveo
Top Alzheimer's Missteps of 2012
Motley Fool
Mon, 12/31/12 - 11:14 am
Alzheimer's disease
Medivation
Pfizer
Eli Lilly
JNJ
Merck
Court rules against Medivation in fight with UCLA over cancer drug
Yahoo/Fly on the Wall
Mon, 12/24/12 - 10:40 am
Medivation
UCLA
Aragon
Xtandi
prostate cancer
It's Hard to Make Money When FDA Approvals Are Priced In
Motley Fool
Mon, 12/17/12 - 09:31 am
FDA
drug approvals
Ariad Pharmaceuticals
Novartis
Dendreon
Medivation
Bayer
ONYX Pharmaceuticals
Otsuka
Bristol-Myers Squibb
10 Drugs Approved by the FDA in 2012 to Be Thankful For
Motley Fool
Sat, 12/15/12 - 01:28 pm
Xtandi
Medivation
prostate cancer
Stribild
Gilead Sciences
HIV
Belviq
Arena Pharmaceuticals
obesity
weight loss
Qsymia
Vivus
Kyprolis
ONYX Pharmaceuticals
Multiple Myeloma
Omontys
Affymax
anemia
Linzess
irritable bowel syndrome
Ironwood Pharmaceuticals
Bosulif
chronic myeloid leukemia
Pfizer
Amyvid
Alzheimer's disease
Eli Lilly
Eylea
macular degeneration
Regeneron
Celgene, NPS Pharmaceuticals, Amarin, J&J, Medivation Among Stocks to Watch in December
Minyanville
Fri, 11/30/12 - 04:28 pm
NPS Pharmaceuticals
Medivation
JNJ
Celgene
Amarin

Pages